《美股業績》美國政府大數據外判商Palantir(PLTR.US)收入預測遜預期 股價挫14%
美國政府大數據分析外判商Palantir(PLTR.US)公布第二季業績。季度虧損1.79億美元,按年擴大29%。每股季度攤薄虧損9美仙,經調整後虧損1美仙,差於市場預期的盈利3美仙。季度收入4.73億美元,按年升26%。
公司預期全年收入介乎19億至19.02億美元,低於市場預期的19.6億美元。該股昨日(8日)跌14.2%報9.82美元,市值逾160億美元。
公司於2003年創辦,最初協助美國政府反恐,其後業務擴至商業領域,目前近半銷售來自商界,國際業務收益佔整體約四成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.